Airain Ltd’s Novavax NVAX Stock Holding History

Airain Ltd’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,771	Closed	-$840K	–	1000
2015 Q2	$840K	Buy	+3,771	New	+$663K	0.05%	395
2014 Q2	–	Sell	-10,702	Closed	-$970K	–	874
2014 Q1	$970K	Buy	+10,702	New	+$1.2M	0.17%	218

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Airain Ltd's NVAX Position: Q3 2015 in Review

Airain Ltd sold out of Novavax (NVAX) in Q3 2015, closing a stake of 3,771 shares — an estimated $840K sold.

Airain Ltd first reported a position in NVAX in Q1 2014 and held it in 2 quarters. The position peaked at $970K in Q1 2014. 190 funds tracked by Wall St. Rank hold NVAX as of Q3 2015.

Airain Ltd reported no remaining Novavax position as of Q3 2015 after selling out during the quarter.
Airain Ltd sold 3,771 Novavax shares in Q3 2015, an estimated $840K.
Airain Ltd first reported a position in Novavax in Q1 2014 and held it in 2 quarters.
Airain Ltd's Novavax position peaked at $970K in Q1 2014.
190 funds tracked by Wall St. Rank held Novavax as of Q3 2015.

Based on Airain Ltd's 13F filing for Q3 2015, filed 9 Nov 2015.